Expression and Characterization of Murine Hevin (SC1), a Member of the SPARC Family of Matricellular Proteins
Department of Vascular Biology, The Hope Heart Institute, Seattle, Washington
Correspondence to: E. Helene Sage, PhD, Dept. of Vascular Biology, The Hope Heart Institute, 1124 Columbia St., Seattle, WA 98104-2046. E-mail: hsage{at}hopeheart.org
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
(J Histochem Cytochem 52:735748, 2004)
Key Words: hevin/SC1 matricellular SPARC ECM monoclonal antibodies
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The function of hevin is unclear. However, analysis of hevin activity in vitro has shown that it can modulate cell shape and cell adhesion to different substrates, including fibronectin (Girard and Springer 1996). Hevin is thought to participate in lymphocyte transendothelial migration in high endothelial venules and might alter vascular permeability, in a manner similar to SPARC (Girard and Springer 1996
). Interestingly, the N-terminal portion of hevin augments B-cell lymphopoiesis and clonal proliferation of mature lymphocytes through an undefined mechanism that requires interaction of hevin with B-lymphocytes and is dependent on divalent cations (Oritani et al. 1997
). Hambrock et al. (2003)
have recently described the production and purification of recombinant hevin, and have reported its binding to collagen I fibrils and to the ECM secreted by osteosarcoma cells in vitro.
Levels of hevin/SC1 expression are apparently regulated differentially in neoplastic tissue and in tissue undergoing repair (McKinnon and Margolskee 1996; Mendis et al. 1996
; Nelson et al. 1998
; Isler et al. 2001
; Peters et al. 2001
), data indicating that hevin might modulate cell proliferation. By immunoblotting or Northern analysis, hevin is found in tissues such as brain, lung, kidney, and heart (Hambrock et al. 2003
). A band of Mr 55,000 found in extracts of brain, heart, and muscle (Hambrock et al. 2003
; and unpublished observations) suggests that hevin is specifically cleaved posttranslationally or that an alternative transcript is present in some cells. In addition to SPARC and other ECM components, hevin has recently been associated with the activated stromal (desmoplastic) response of host tissue to adenocarcinomas that develop in the pancreas (Ryu et al. 2001
; Iacobuzio-Donahue et al. 2002
,2003
). In situ hybridization studies demonstrate mRNA encoding hevin in angiogenic endothelial cells in stromal areas of invasive pancreatic adenocarcinoma (Iacobuzio-Donahue et al. 2002
). Other analyses cataloging the level of hevin mRNA in cancerous tissues have shown that levels of hevin decrease in tumor cells (Bendik et al. 1998
; Claeskens et al. 2000
). The apparent context-dependent expression of hevin is consistent with the regulation of other matricellular proteins (SPARC, thrombospondins, CCN proteins) in tumor tissue (Brekken and Sage 2001
). Interestingly, and consistent with results from other mice with targeted deletions of certain matricellular genes, hevin-null mice do not display obvious differences from wild-type littermates (McKinnon et al. 2000
). However, responses of hevin-null mice to challenges have demonstrated phenotypes with respect to wound healing and foreign body response that are distinct from those of wild-type and of SPARC-null mice (M. Sullivan et al., unpublished observations). Compensation of hevin function by other SPARC family proteins is also a possibility that should not be overlooked in the interpretation of the hevin-null phenotype.
We have expressed recombinant mouse hevin in insect cells and have developed a protocol for its purification. Recombinant hevin was the antigen for the production of rat anti-hevin monoclonal antibodies (MAbs) that have been used to characterize the synthesis and distribution of hevin in normal and neoplastic tissues. We show that recombinant hevin inhibited the spreading of endothelial cells in vitro in a time- and concentration-dependent manner. These functions are reminiscent of those of SPARC and other matricellular proteins and implicate hevin in a variety of cellECM interactions that affect development and response to injury.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
For purification, 1/10 volume of 200 mM 3-(N-morpholino) propane sulfonic acid (Mops, pH 6.5) was added to the starting material and the pH was adjusted to 6.5. The supernatant was applied to a column (1.7 x 20 cm) containing Q-Sepharose Fast Flow anion-exchange resin (Amersham Biosciences; Piscataway, NJ), equilibrated in 200 mM LiCl, 20 mM Mops (pH 6.5). Recombinant hevin was eluted from the column with a continuous salt gradient from 200 to 600 mM LiCl, 20 mM Mops (pH 6.5). The peak fractions were identified by spectrophotometry and were confirmed by SDS-PAGE and staining with Coomassie Brilliant Blue R (Laemmli 1970). Fractions containing recombinant hevin were pooled, dialyzed against Hanks buffered saline solution (HBSS), flash frozen in liquid N2, and stored at 80C.
Further purification was achieved by size-exclusion chromatography and/or isoelectric focusing: For size-exclusion chromatography, peak fractions from the anion-exchange chromatography (described above) were pooled, concentrated in a Centricon Plus-80 centrifugal filter device with 30,000-kD molecular weight cut-off (Millipore; Bedford, MA), and applied to a column (16 x 100 cm) containing Superdex 200 (Amersham Biosciences) equilibrated with HBSS without glucose, 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5. The peak fractions were identified by spectrophotometry, SDS-PAGE, and staining with Coomassie Brilliant Blue R. The fractions containing recombinant hevin of highest purity were pooled, dialyzed against HBSS, concentrated, flash-frozen in liquid nitrogen, and stored at 80C. For isoelectric focusing, peak fractions from anion-exchange chromatography were pooled and concentrated as above and were purified by continuous native-PAGE (pH 6.6) on a Model 491 Prep Cell (Bio-Rad Laboratories; Hercules, CA) according to the manufacturer's instructions. Fractions containing recombinant hevin were identified as above, pooled, dialyzed against HBSS, concentrated, flash-frozen in liquid nitrogen, and stored at 80C.
Recombinant hevin, or recombinant hevin digested for 30 min at 37C with trypsin (Worthington Biochemicals; Lakewood, NJ; 1:500 molar ratio of trypsin to hevin) was resolved by SDS-PAGE under reducing conditions, electrophoretically transferred to a PVDF membrane, and subjected to N-terminal sequencing (B. McMullen and E. Davie, Department of Biochemistry, University of Washington, Seattle, WA).
Endotoxin levels were quantified with the Limulus Amebocyte Lysate Pyrochrome kit (Associates of Cape Cod; Falmouth, MA) according to the manufacturer's instructions.
Generation and Screening of Hybridomas
Male SpragueDawley rats were immunized IP with 50 µg of recombinant hevin in Ribi R-700 adjuvant (Corixa; Hamilton, MT). After two boosts with the same mixture on days 21 and 42 and a final IP boost without adjuvant on day 63, spleens were collected under sterile conditions on day 66. Splenocytes were fused with P3-X63-Ag8.653 mouse myeloma cells (American Type Culture Collection; Rockville, MD) according to established procedures (Kearney et al. 1979; Lane 1985
). The resulting cell mixture was plated into multiple 96-well tissue culture plates in medium consisting of Iscove's modified Dulbecco's medium (Gibco; Grand Island, NY) supplemented with 10% (v/v) Fetal Clone I serum (HyClone Laboratories; Logan, UT), 10% (v/v) BM Condimed H1 (Roche Applied Science; Indianapolis, IN), 2 mM L-glutamine (Gibco), 100 U/ml penicillin G (sodium salt) and 100 µg/ml streptomycin sulfate (Gibco), and HAT (0.1 mM hypoxanthine, 0.4 mM aminopterin, 0.016 mM thymidine; Gibco) as a selective agent. The cells were fed on days 4 and 7 after fusion by aspiration and replacement with fresh medium of approximately three-fourths of the medium contents in each well.
On day 9, supernatants from the fusion plates were screened by indirect ELISA. Immulon II plates (Thermo Labsystems; Franklin, MA) were coated with 0.5 µg/ml, 55 ml/well, of recombinant hevin diluted in 10 mM PBS overnight at 4C. Unbound antigen was removed, the wells were washed twice with PBS containing 0.05% Tween-20 (PBST), and the wells were blocked for 1 hr at room temperature with PBST containing 1% (w/v) bovine serum albumin (BSA) (Sigma; St Louis, MO), 200 µl/well. After removal of the blocking solution, the wells were washed twice with PBST, after which culture supernatants from the fusion plates were replica-plated onto ELISA plates at 55 µl/well. The plates were incubated for 1 hr at RT, after which the supernatants were removed and the wells washed four times with PBST. For detection of bound antibody, an HRP-conjugated goat anti-rat IgG (Fc-specific) reagent (Southern Biotechnology Associates; Birmingham, AL) was diluted 1:5000 in Iscove's modified Dulbecco's medium containing 2% Fetal Clone I serum and was added to the wells at 55 µl/well. After a 1-hr incubation at RT, the wells were washed five times with PBST. 3,3'5,5'-Tetramethylbenzidine (TMB) substrate in substrate buffer (Genetic Systems; Redmond, WA) was prepared according to the manufacturer's instructions and was added to the wells (55 µl/well). After a 1015 min incubation at RT, color development in the wells was terminated by the addition of 1 N H2SO4 and the optical density of the wells was read on an ELISA plate reader (Molecular Devices; Sunnyvale, CA) at 450 nm. All supernatants that were positive in this assay were evaluated in a second indirect ELISA using recombinant human SPARC (Bradshaw et al. 2000) as a negative control protein to ensure that the positive supernatants in the initial assay contained antibody that was specific for hevin.
Hybridomas in wells with anti-hevin specificity were cloned at least twice by culturing the cells at an average of less than one cell per well in Costar 96-well half-area plates (Corning; Acton, MA) and assessing specificity of antibody produced by the clones as described above. MAbs produced by each of the final clones were evaluated for IgG subclass and light chain composition with a rat Monoclonal Antibody Isotyping kit (Roche Applied Science).
Antibody Purification
IgG antibodies were purified from tissue culture supernatant by chromatography on protein G using the Pierce ImmunoPure Binding/Elution buffering system (Pierce; Rockford, IL). IgGs were evaluated for purity by SDS-PAGE and staining with Coomassie Brilliant Blue R and for reactivity with recombinant hevin by indirect ELISA.
Capture ELISA
Recombinant hevin was biotinylated by incubation of biotinamidocaproate NHS-ester (Sigma) with hevin at a 20:1 molar ratio in HBSS (Gibco). The solution was rotated gently at RT for 1.5 hr, after which the reaction was stopped by addition of Tris-HCl/glycine (pH 8) to a final concentration of 10 mM. Biotinylated hevin was separated from excess biotin on a PD-10 column (Amersham Biosciences). For the capture ELISA, microtiter plates coated with protein G (Pierce) or purified IgG (100 ng/well) were blocked with 5% casein acid hydrolysate (CAH) (Sigma) and were incubated with biotinylated hevin at various concentrations. Peroxidase-conjugated NeutrAvidin (NA-Hrp) (Pierce) was added as a second layer, and reactive wells were developed with the peroxidase substrate TMB (BioFx Laboratories; Owings Mills, MD). Reactions were stopped after 15 min with 1 M H3PO4 and were read spectrophotometrically at 450 nM.
Immunoblotting
A total of 250 ng of purified recombinant hevin, 75 µg of whole mouse brain lysate (Brekken et al. 2000), and 75 µg of whole hevin-null mouse brain lysate were resolved by SDS-PAGE on a 412% Bis-Tris polyacrylamide gel (Invitrogen) under reducing conditions (100 mM DTT added to protein samples). Proteins were transferred to Immun-Blot PVDF membranes (Bio-Rad) and were blocked for 1 hr at RT with AquaBlock (East Coast Biologics; North Berwick, ME). Each membrane was incubated with an anti-hevin MAb at 1 µg/ml, or antibody tissue culture supernatant at a dilution of 1:10, in PBST + 0.05% CAH for 1 hr at RT or overnight at 4C, followed by washes with PBS + 0.2% Tween-20. The membranes were developed with Super Signal West Pico chemiluminescence substrate (Pierce) after incubation with peroxidase-conjugated goat anti-rat secondary antibodies (Jackson ImmunoResearch Laboratories; West Grove, PA) according to the manufacturers' instructions. Equal transfer of the proteins is routinely confirmed by staining of the transferred gels with Coomassie Brilliant Blue R.
Immunoprecipitation
One ml of conditioned media (CM) from hevin-infected sf9 cultures, or 1 ml of HBSS spiked with 500 ng of purified recombinant mouse hevin, was mixed with 200 µl of anti-hevin MAb 1218 tissue culture supernatant or 25 µg of purified 1218 and was incubated for 2 hr at 4C. The IgG was precipitated by the addition of protein G-Sepharose beads, and the precipitate was washed three times with PBS/0.5% CAH/0.2% Tween-20. Proteins were resolved after disulfide-bond reduction by SDS-PAGE on a 412% Bis-Tris polyacrylamide gel. The presence of hevin in the precipitate was determined by immunoblotting with MAb 155 (1.0 µg/ml).
Immunohistochemistry and Immunocytochemistry
Formalin- and methyl Carnoy's-fixed tissues embedded in paraffin were sectioned by the Histopathology Laboratory at the University of Washington. Methyl Carnoy's-fixed sections were deparaffinized under standard conditions. If necessary, endogenous peroxidases were blocked in methanol with 1.0% H2O2 for 30 min. Some of the sections were subsequently treated with Autozyme (10 µl enzyme concentrate/1 ml buffer for 6 min at RT) (BioMeda; Foster City, CA). The sections were incubated with primary antibody for 1 hr, washed with PBST, incubated for 1 hr with the appropriate peroxidase-labeled secondary antibody (Jackson ImmunoResearch), developed with stable diaminobenzidine (DAB) (ResGen; Huntsville, AL), counterstained with hematoxylin, and cover slipped in Permount (Fisher; Fair Lawn, NJ). Paraffin-embedded sections of mouse brain were evaluated for reactivity as described above except that reactivity was visualized by the use of appropriate fluorescently labeled secondary antibodies (Jackson ImmunoResearch). MAb TUJ1 (BabCO; Berkeley, CA) was used as a neuron marker. Sections of frozen tissue (57 µm) were air-dried, fixed in fresh acetone for 5 min, rehydrated in PBST, and blocked in PBST containing 20% Aquablock (East Coast Biologics) for 30 min. The slides were incubated with primary antibodies and were developed as described above.
Acetone-fixed frozen sections of human tumor xenografts grown in SCID mice and tumor specimens from patients obtained from the National Cancer Institute Cooperative Human Tissue Network (Southern Division; Birmingham, AL) were evaluated for reactivity with the anti-hevin MAbs as described above, except that the peroxidase substrate aminoethylcarbazole (AEC) used was as the chromogen.
We screened the MAbs for reactivity with bovine aortic endothelial cells (BAECs) (passage 10; isolated and propagated in our laboratory) (Funk and Sage 1991) plated onto glass coverslips and grown to 70% confluence in DMEM with 10% FBS. Cells were washed once with PBS, incubated at 37C for 30 min in serum-free DMEM (SFM), fixed with 3% formaldehyde/SFM for 20 min at RT, and rinsed with PBS. Cells were blocked with 5% normal goat serum in PBST for 20 min at RT and the anti-hevin MAbs were added at concentrations of 10, 5, and 2.5 µg/ml for 1 hr at RT. Negative controls were normal rat serum and the secondary antibody alone. Reactivity was detected by incubation of the coverslips with the appropriate fluorescein (FITC)-conjugated secondary antibody (Jackson ImmunoResearch). The coverslips were rinsed and nuclei were stained with 20 µg/ml Hoechst 22258 in PBS (Molecular Probes; Eugene, Oregon) for 3 min at RT, washed in PBS, and mounted on slides with Vectashield mounting medium (Vector Laboratories; Burlingame, CA).
Adhesion Assays In Vitro
BAECs (passages 512) were plated in DMEM into 24-well tissue culture plates (Corning) at 104 cells/well. Recombinant hevin (10 or 40 µg/ml) was added immediately to cells in suspension and the cells were monitored hourly by phase-contrast microscopy, up to 24 hr. Alternatively, tissue culture wells were precoated overnight at 4C with 10 µg/ml fibronectin (Biomed-Tech; Ancona, Italy) or hevin and were washed once with Dulbecco's PBS. BAEC were subsequently plated in serum-free DMEM at 104 cells/well, and cells were monitored by phase-contrast microscopy from 30 min to 24 hr. Quantification of cell spreading was performed by calculation of a Rounding Index, as described by Lane and Sage (1990).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Figures 1 and 2
illustrate the purification of hevin from the culture medium of Sf9 cells transfected with the baculoviral expression vector described in Materials and Methods. Chromatography on Q-Sepharose (Figure 1) produced hevin of Mr 120,000130,000 as estimated by SDS-PAGE on 10% polyacrylamide gels (Figure 1C, Lane 2). Despite the calculated peptide mass of hevin (70,900 D), this size range is consistent with published results (Johnston et al. 1990; Girard and Springer 1995
,1996
; Mendis et al. 1996
) and with the apparent Mr of hevin from mouse brain extract (Figure 1C, Lane 3). The apparent Mr of recombinant hevin was only slightly altered in the presence of DTT (Figure 1B, Lanes 3 and 6). The sequence in the expression vector encoding hevin has been verified by dideoxy sequencing of multiple overlapping products. In addition, protein sequence analysis of the N-terminus and of trypsin-derived peptides of the purified product has validated the protein as hevin, with a 14-residue N-terminal leader derived from the pAcGP67A vector. Recombinant hevin is glycosylated by Sf9 cells (not shown), but the presence of other carbohydrate modifications, coupled with its low pI, account for the low mobility of hevin on SDS-PAGE gels (Figure 1C; and Hambrock et al. 2003
).
|
|
Recoveries of recombinant hevin are shown in Table 1. Based on scanning densitometry of SDS-polyacrylamide gels, which tends to overestimate the contribution of impurities, preparations of recombinant hevin were 80% pure after elution from an isoelectric focusing column. Greater yields, however, with less purity, were obtained from size-exclusion chromatography compared with isoelectric focusing.
|
|
|
|
|
|
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Among the many cell lines that have been tested for the production of hevin, the few that produce hevin at detectable levels by immunoblotting are tumor lines. Lysates of hevin-producing tumor cells yield a primary immunoreactive band of Mr 130,000 on SDS-PAGE using 10% polyacrylamide gels (not shown). We found hevin of similar Mr in lysates of human and mouse brain tissue, or of Mr 105,000 on 412% Bis-Tris gradient gels. The major immunoreactive band of recombinant mouse hevin migrates slightly faster than the Mr 130,000 band characteristic of cell and tissue lysates, a possible consequence of the inability of insect cells to produce N-glycoproteins containing a sialic acid cap, a modification of many complex carbohydrate chains of secreted proteins synthesized by mammalian cells. Note that the apparent Mr of recombinant hevin is 105,000 when estimated by separation on a NuPAGE 412% Bis-Tris gel with NuPAGE MOPS SDS running buffer (Invitrogen) (Figure 6). Estimates of the Mr of human hevin in the literature vary from 95,000 (Hambrock et al. 2003) to 150,000 (Bendik et al. 1998
) by SDS-PAGE. Therefore, we consider acceptable the apparent size variation that we have observed in recombinant murine hevin and explain it as a possible consequence of the gel resolution system and/or interaction of the acidic N-terminal domain with buffers of varying pH and/or ionic strength.
The de-adhesive effects of hevin that we report are consistent with a prior study. Girard and Springer (1996) found that hevin (in contrast to fibronectin, thrombospondin 1, and tenascin C) was non-permissive for attachment and spreading by HUVECs and BAECs. Furthermore, it diminished adhesion to fibronectin, an effect correlated with reduced formation of focal adhesions. Initially, it was suggested that hevin supported lymphocyte extravasion through high endothelial venules via the diminishment of cellcell and/or cellECM contacts in a dynamic, chemokine-responsive manner (Girard and Springer 1995
,1996
). We speculate that hevin might play a comparable role in the desmoplastic endothelium associated with tumor growth and metastasis.
The expression and function of hevin in neoplastic tissue appear to be dependent upon the microenvironment, consistent with the expression and function of the hevin homologue SPARC in tumors. For example, SPARC promotes invasiveness in brain tumors (astrocytomas and glioblastomas) (Golembieski et al. 1999; Menon et al. 2000
) but induces tumor cell apoptosis in ovarian carcinomas (Yiu et al. 2001
). Hevin has been suggested as a potential tumor suppressor due to its downregulation in multiple cancers and its effects on cell proliferation in vitro (Bendik et al. 1998
; Claeskens et al. 2000
; Isler et al. 2001
). However, hevin is also upregulated in the desmoplastic response (Ryu et al. 2001
; Iacobuzio-Donahue et al. 2002
). Pancreatic adenocarcinomas and renal cell carcinomas, in comparison to normal pancreas or kidney, have been shown to express increased levels of hevin, as determined by SAGE and gene expression profiling (Peale and Gerritsen 2001
; Ryu et al. 2001
; Iacobuzio-Donahue et al. 2002
), and ISH indicated that endothelial cells in the desmoplastic regions of the tumors were primarily responsible for the production of hevin (Ryu et al. 2001
; Iacobuzio-Donahue et al. 2002
). In contrast, we found that hevin was expressed in or on luminal duct epithelial cells in frozen sections of human endometrial adenocarcinoma (Figure 8), but we did not find hevin in two examples of human pancreatic adenocarcinoma. These discrepancies might be resolved by time-course studies of tumor development and by analysis of the type and degree of desmoplasia associated with each tumor. Hevin was also evident in human pancreatic tumor xenografts grown in immunocompromised mice, although there were different patterns of anti-hevin immunoreactivity in these tissues. Some MAbs reacted clearly with stromal components that included endothelial cells and ECM, whereas other MAbs reacted with distinct stromal cells as well as tumor cells.
The function of hevin in the regulation of tissue growth, reaction to injury, and remodeling is not clear, especially with the claim that hevin-null mice lack a discernable phenotype and display no alterations in SPARC levels, in comparison to wild-type mice (McKinnon et al. 2000). SPARC-null mice also do not show major alterations in hevin, as determined by IHC (RAB, unpublished observation). Therefore, the speculation that SPARC and hevin might functionally compensate for each other, although possible, is thus far unsupported. Mice lacking both SPARC and hevin are viable, and studies assessing the responses of these mice to injury are under way (Puolakkainen et al. unpublished observations). Like SPARC, hevin has recently been shown to associate with collagen I fibers in vitro (Hambrock et al. 2003
), and IHC analysis of different tissues, particularly subcutaneous tumor xenografts, indicates that hevin is associated with ECM components. Therefore, consistent with a major function of SPARC, hevin might regulate the production, deposition, and/or assembly of ECM proteins or proteoglycans, such as collagen or decorin (Bradshaw et al. 2003
; Brekken et al. 2003
). Although this idea has not been tested directly, it is important to note that the tools for a thorough examination of the function of hevin are now available. Recombinant hevin, MAbs specific for hevin, hevin-null mice, and hevin/SPARC double-null mice will enable us to probe into the mechanisms by which hevin regulates cell adhesion in vitro and possibly desmoplasia in vivo.
![]() |
Acknowledgments |
---|
We thank members of the Sage Laboratory and Dr D. Graves for helpful comments, Dr. E. Davie and B. McMullen for sequencing, and Eileen Neligan for assistance with the manuscript.
![]() |
Footnotes |
---|
2 Present address: Gazes Cardiac Research Institute, Medical University of South Carolina, Charleston, SC.
3 Present address: Department of Immunology, Zymogenetics Inc., Seattle, WA.
Received for publication December 26, 2003; accepted February 24, 2004
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bendik I, Schraml P, Ludwig CU (1998) Characterization of MAST9/hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res 58:626629[Abstract]
Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14:608616[CrossRef][Medline]
Bradshaw AD, Bassuk JA, Francki A, Sage EH (2000) Expression and purification of recombinant human SPARC produced by baculovirus. Mol Cell Biol Res Commun 3:345351[CrossRef][Medline]
Bradshaw AD, Lara S, Wight T, Sage EH (2003) SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Dermatol 120:949955
Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:51175124
Brekken RA, Puolakkainen P, Workman G, Graves DC, Lubkin SR, Sage EH (2003) Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111:487495
Brekken RA, Sage EH (2001) SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19:816827[Medline]
Claeskens A, Ongenae N, Neefs JM, Cheyns P, Kaijen P, Cools M, Kutoh E (2000) Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer 82:11231130[CrossRef][Medline]
Funk SE, Sage EH (1991) The Ca2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci USA 88:26482652[Abstract]
Girard JP, Springer TA (1995) Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 2:113123[Medline]
Girard JP, Springer TA (1996) Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem 271:45114517
Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA (1999) Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci 17:463472[CrossRef][Medline]
Gongidi V, Ring C, Brekken R, Sage EH, Rakic P, Anton ES (2004) SPARC-like 1 is a radial glia-associated terminator of neuronal migration in cerebral cortex. Neuron 41:5769[CrossRef][Medline]
Hambrock HO, Nitsche DP, Hansen U, Bruckner P, Paulsson M, Maurer P, Hartmann U (2003) SC1/hevin, an extracellular calcium-modulated protein that binds collagen I. J Biol Chem 278:1135111358
Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, et al. (2003) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162:11511162
Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE (2002) Exploring the host desmoplastic response to pancreatic carcinoma. Am J Pathol 160:9199
Isler SG, Schenk S, Bendik I, Schraml P, Novotna H, Moch H, Sauter G, et al. (2001) Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol 18:521526[Medline]
Johnston IG, Paladino T, Gurd JW, Brown IR (1990) Molecular cloning of SC1: a putative brain extracellular matrix glycoprotein showing partial similarity to osteonectin/BM40/SPARC. Neuron 4:165176[Medline]
Kearney JF, Radbruch A, Liesegang B, Rajewsky K (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123:15481550[Abstract]
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680685[Medline]
Lane RD (1985) A short-duration polyethylene glycol fusion technique for increasing production of monoclonal antibody-secreting hybridomas. J Immunol Methods 81:223228[CrossRef][Medline]
Lane TF, Sage EH (1990) Functional mapping of SPARC: peptides from two distinct Ca++-binding sites modulate cell shape. J Cell Biol 111:30653076[Abstract]
McKinnon PJ, Margolskee RF (1996) SC1: a marker for astrocytes in the adult rodent brain is upregulated during reactive astrocytosis. Brain Res 709:2736[CrossRef][Medline]
McKinnon PJ, McLaughlin SK, Kapsetaki M, Margolskee RF (2000) Extracellular matrix-associated protein SC1 is not essential for mouse development. Mol Cell Biol 20:656660
Mendis DB, Ivy GO, Brown IR (1996) SC1, a brain extracellular matrix glycoprotein related to SPARC and follistatin, is expressed by rat cerebellar astrocytes following injury and during development. Brain Res 730:95106[CrossRef][Medline]
Menon PM, Gutierrez JA, Rempel SA (2000) A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol 17:683693[Medline]
Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY, et al. (1998) Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res 58:232236[Abstract]
Oritani K, Kanakura Y, Aoyama K, Yokota T, Copeland NG, Gilbert DJ, Jenkins NA, et al. (1997) Matrix glycoprotein SC1/ECM2 augments B lymphopoiesis. Blood 90:34043413
Peale FV Jr, Gerritsen ME (2001) Gene profiling techniques and their application in angiogenesis and vascular development. J Pathol 195:719[CrossRef][Medline]
Peters DG, Kassam AB, Feingold E, Heidrich-O'Hare E, Yonas H, Ferrell RE, Brufsky A (2001) Molecular anatomy of an intercranial aneurysm: coordinated expression of genes involved in wound healing and tissue remodeling. Stroke 32:10361042
Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE (2001) Characterization of MAST9/hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res 61:18331838
Sato C, Matsuda T, Kitajima K (2002) Neuronal differentiation-dependent expression of the disialic acid epitope on CD166 and its involvement in neurite formation in neuro2A cells. J Biol Chem 277:4529945305
Soderling JA, Reed MJ, Corsa A, Sage EH (1997) Cloning and expression of murine SC1, a gene product homologous to SPARC. J Histochem Cytochem 45:823835
Sullivan M, Sage EH (2004) Hevin. Int J Biochem Cell Biol (in press)
Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159:609622